VALGENT: A protocol for clinical validation of human papillomavirus assays
详细信息 查看全文
- 作者：Marc Arbyna ; marc.arbyn@wiv-isp.be" class="auth_mail" title="E-mail the corresponding author ; Christophe Depuydtb ; Ina Benoyb ; Johannes Bogersb ; Kate Cuschieric ; Markus Schmittd ; Michael Pawlitad ; Daan Geraetse ; Isabelle Heardf ; Tarik Gheitg ; Massimo Tommasinog ; Mario Poljakh ; Jesper Bondei ; Wim Quinte
- 关键词：EIA ; enzyme immunoassay ; ASC-US ; atypical squamous cervical cells of undetermined significance ; CIN ; cervical intraepithelial neoplasia ; LSIL ; low-grade squamous intraepithelial lesion ; HPV ; human papillomavirus ; Hr ; high-risk ; HSIL ; high-grade squamous intraepithelial lesion ; SHPVRL ; Scottish HPV Reference Laboratory ; VALGENT ; VALidation of HPV GENotyping tests
- 刊名：Journal of Clinical Virology
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：76
- 期：supp_S1
- 页码：S14-S21
- 全文大小：574 K
文摘
- •
Only clinically validated HPV tests should be used in cervical cancer screening.
- •
VALGENT is a robust protocol for validation of hrHPV and HPV genotyping assays.
- •
In VALGENT-2 sufficient clinical accuracy of three HPV assays was demonstrated.
- •
VALGENT is producing a comprehensive study resource for HPV test comparisons.
- •
Integration of VALGENT into the global WHO reference laboratory network is planned.